Pacira BioSciences, Inc.

Pacira BioSciences, Inc.

PCRXยทNASDAQ

$22.32

+0.31%
HealthcareDrug Manufacturers - Specialty & Generic

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

At a Glance

Live Snapshot
Market Cap$877.96M
EPS0.1600
P/E Ratio139.50
Earnings Date08/04/2026
0.00%
Dividend Yield
3Y-
5Y-
10Y-
0.00%
Dividend Payout Ratio
3Y-
5Y-
10Y-
Pacira BioSciences, Inc.

Pacira BioSciences, Inc. Dividend History

PCRX ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

PCRX Dividend Payment History

PCRX ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
pcrx

Pacira BioSciences, Inc. Payout Ratio Analysis

PCRX ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
7.03M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Excellent FCF coverage. Dividend is well-supported by actual cash generation with ample room for increases and business reinvestment.

Sustainability
Fair

Dividend sustainability questionable. Monitor closely for signs of stress. Consider whether yield justifies the risk.